Significantly Rerated by European/US Analyst's Report
Melbourne, Feb 15, 2017 AEST (ABN Newswire) - Immuron Limited (
ASX:IMC) (IMROY:OTCMKTS) (the "Company") wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van Leeuwenhoeck Institute ("VLI"), has published an updated in-depth Research Report on the Company and its R&D programs.
The report provides a full valuation of Immuron's Intellectually Property Assets including its current pipeline of development programs.
VLI provides institutional investors and other professional investors with independent, un-biased research on the real value of innovative Life Sciences companies.
To view the Research Report, please visit:
http://www.abnnewswire.net/lnk/M2MHXP1K
About Immuron Limited
Immuron Limited (ASX:IMC) (OTCMKTS:IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan(R) for the prevention of travellers' diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.
For more information visit: Immuron Website
| ||
|
